Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J00-J99- Diseases of the respiratory system
Conditions
Interventions
Intervention1: Cordyceps capsules 500 mg plus standard treatment: Cordyceps 500 mg capsule will be administered three times a day after food as an add-on to the standard therapy. Treatment will be giv
Sponsors
Ambrosia Food Farm Co
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with mild to Moderate Category COVID-19 patients 2. Male or female patients �18 years of age. 3. Patients with or without co-morbidities (stable diabetes or/and hypertension with medications). 4. Voluntary willingness to give written informed consent prior to participation in trial. 5. Male patients who is willing to follow contraceptive measures . 6. Female should be of non-childbearing potential, either surgically sterile or postmenopausal. 7. Female of childbearing potential should agree to use effective contraceptive measures 8. Willingness and ability to comply with trial and follow-up procedures.
Exclusion criteria
Exclusion criteria: 1. Patients who refuse to give consent for participation. 2. Patients with severe COVID-19 infection 3. Patient with asymptomatic infection. 4. Patients who are allergic to Cordyceps Capsules. 5. Patients already enrolled in another intervention trial. 6. Patients who receive immunomodulant therapy like Tocilizumab or convalescent plasma or high-dose pulse steroid therapy. 7. Autoimmune diseases such as multiple sclerosis (MS), systemic lupus erythematosus (SLE) rheumatoid arthritis (RA) other conditions. 8. Patients with any bleeding disorder e.g. hemophilia and von Willebrand disease. 9. Patients in whom the surgeries are planned during the study. 10. Pregnant or breastfeeding. 11. Concurrent condition that in the investigatorââ?¬•s opinion would jeopardize compliance with the protocol. 12. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients showing improvement in clinical symptomsTimepoint: Within 30 days | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Number of patients developing severe COVID-19 infection 2. The proportion of the patients reporting negative COVID-19 test (2019-nCoV RT-PCR) 3. Improvement in oxygenation indices 4. The reduction of inflammatory markers 5. Length of hospital stay 6. Duration of Oxygen requirement. 7. Adverse event reportedTimepoint: 1. Day 30 2. Day 15 3. Day 10 4. Day 5 and Day 10 as compared to baseline 5. Within 30 days 6. Within 30 days 7. Within 30 days | — |
Countries
India
Contacts
Public ContactDr Sagar Sinha
MGM Medical College and Hospital Navi Mumbai
Outcome results
None listed